A detailed history of Black Rock Inc. transactions in Cor Medix Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,553,474 shares of CRMD stock, worth $40.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,553,474
Previous 3,486,994 1.91%
Holding current value
$40.3 Million
Previous $14.8 Million 4.07%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.08 - $6.39 $271,238 - $424,807
66,480 Added 1.91%
3,553,474 $15.4 Million
Q1 2024

May 10, 2024

SELL
$2.94 - $4.24 $60,860 - $87,772
-20,701 Reduced 0.59%
3,486,994 $14.8 Million
Q4 2023

Feb 13, 2024

BUY
$3.0 - $4.01 $1.05 Million - $1.4 Million
349,037 Added 11.05%
3,507,695 $13.2 Million
Q3 2023

Nov 13, 2023

BUY
$3.6 - $4.46 $1.56 Million - $1.94 Million
433,961 Added 15.93%
3,158,658 $11.7 Million
Q2 2023

Aug 11, 2023

BUY
$3.94 - $5.8 $8.2 Million - $12.1 Million
2,081,542 Added 323.65%
2,724,697 $10.8 Million
Q1 2023

May 12, 2023

BUY
$3.22 - $4.61 $7,525 - $10,773
2,337 Added 0.36%
643,155 $2.66 Million
Q4 2022

Feb 13, 2023

BUY
$2.81 - $4.45 $21,493 - $34,038
7,649 Added 1.21%
640,818 $2.7 Million
Q3 2022

Nov 14, 2022

SELL
$2.82 - $7.52 $12,997 - $34,659
-4,609 Reduced 0.72%
633,169 $1.79 Million
Q2 2022

Aug 12, 2022

SELL
$2.73 - $5.61 $4.87 Million - $10 Million
-1,785,439 Reduced 73.68%
637,778 $2.56 Million
Q1 2022

May 12, 2022

SELL
$3.83 - $6.24 $296,840 - $483,624
-77,504 Reduced 3.1%
2,423,217 $13.3 Million
Q4 2021

Feb 10, 2022

SELL
$4.47 - $5.56 $25,358 - $31,541
-5,673 Reduced 0.23%
2,500,721 $11.4 Million
Q3 2021

Nov 09, 2021

BUY
$4.46 - $7.11 $59,674 - $95,131
13,380 Added 0.54%
2,506,394 $11.7 Million
Q2 2021

Aug 11, 2021

BUY
$6.05 - $10.09 $15.1 Million - $25.2 Million
2,493,014 New
2,493,014 $17.1 Million

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $468M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.